GLP-1 receptor agonist

Semaglutide

Once-weekly injectable GLP-1 agonist. Approved as Ozempic (T2D), Wegovy (weight management), and Rybelsus (oral T2D). Compounded versions are dispensed by 503A/B pharmacies under prescriber order.

Trial outcome — STEP 1 (NEJM 2021)

14.9% body-weight reduction at 68 weeks vs 2.4% placebo, in adults with overweight/obesity without diabetes

Dose schedule

0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg over 16+ weeks

Common side effects

  • • Nausea
  • • Constipation
  • • Diarrhea
  • • Fatigue (titration)
  • • Reflux

Contraindications

  • • Personal/family history of medullary thyroid carcinoma
  • • MEN-2 syndrome
  • • Pregnancy
  • • Active gallbladder disease
  • • Severe gastroparesis

FAQ

Is semaglutide right for me?
A licensed prescriber will determine that based on your BMI, medical history, and goals. We can match you with one.
How fast will I see results?
Most patients see meaningful weight reduction within the first 8–12 weeks of titration. Peak effect typically occurs around 60–68 weeks.
What if I stop?
Most patients regain some weight after stopping. Talk with your prescriber about a long-term maintenance plan.
Get matched

Want a real recommendation?

Five minutes. Free. No pressure.

Start my consultation